Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX66 in Hospitalized Moderate COVID-19 Patients
NCT04555213Phase 1Completed
- Sponsor
- Noxopharm Limited
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of idronoxil in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Noxopharm Limited. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 60 Days. Started Sep 2020; status: completed.
02
Drugs
idronoxil
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04555213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555213.